Moderna Updates: Favorable Data In Older Participants, E.U. Supply Deal

Moderna, a frontrunner in the development of a Covid-19 vaccine, saw its stock rally by close to 10% over the last two days. Below we provide a quick update on some of the recent developments for the company. Based on interim data from its Phase 1 clinical trial, Moderna indicated that the immune...